Sales marketing Email：peptidedb@qq.com
| Bioactivity |
Azenosertib (ZN-c3) is a selective, orally active inhibitor for Wee1 inhibitor (IC50=3.9 nM). Azenosertib exhibits antitumor activity[1]. |
| Target |
IC50: 3.9 nM (Wee1) |
| Invitro |
Azenosertib 抑制癌细胞 H23 和 A427 的增殖，IC50 为 103 和 75 nM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Azenosertib 相关抗体: Cell Proliferation Assay[1] Cell Line: |
| In Vivo |
Azenosertib (80 mg/kg，口服 28 天) 抑制 A427 异种移植肿瘤在 NOD/SCID 小鼠模型中的肿瘤生长[1]。Azenosertib (10 mg/kg，口服) 的药代动力学数据表明，Azenosertib 在比格犬模型中的血浆暴露率是Cmax = 2.1 μM，半衰期 T1/2 为 2.3 h，AUC0-24 h 为 9.7 μM·h，口服利用率为 F=142%[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS |
2376146-48-2 |
| Formula |
C29H34N8O2 |
| Molar Mass |
526.63 |
| Appearance |
固体 |
| Transport |
Room temperature in continental US; may vary elsewhere. |
| Storage |
| Powder |
-20°C |
3 years |
|
4°C |
2 years |
| In solvent |
-80°C |
6 months |
|
-20°C |
1 month |
|
| Reference |
[1]. Huang PQ, et al. Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer [published online ahead of print, 2021 Aug 23]. J Med Chem. 2021;10.1021/acs.jmedchem.1c01121. |
